{"id":26154,"title":"G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buerger's disease) and their removal by immunoadsorption.","abstract":"Hintergrund: Histopathologische und serologische Befunde sprechen für eine Immunpathogenese der Thromboangiitis obliterans (TAO, Buerger?sche Erkrankung). Autoantikörper scheinen eine wichtige Rolle im Krankheitsgeschehen zu spielen. Es wurden wiederholt positive therapeutische Effekte durch eine Immunadsorption (IA) gezeigt. Wir analysierten agonistische Autoantikörper (agAAK), die gegen G-Protein gekoppelte Rezeptoren (GPCR) gerichtet sind und analysierten, ob diese durch eine IA effektiv beseitigt werden können. Patienten und Methoden: Zwischen Dezember 2012 und Mai 2014 wurden 11 Patienten mittels IA über 5 konsekutive Tage behandelt. Die agAAK wurden unter Verwendung spezifischer ELISA-Techniken bestimmt. Ergebnisse: AgAAK wurden bei 9 von 11 Patienten (81.8 %) gefunden. Multiple agAAK waren bei 7 Patienten (63.6 %) nachweisbar. Darüber hinaus wurde ein agAAK-Cluster entdeckt, das sich gegen Loop1 des adrenergen ?1-Rezeptors und Loop1 des Endothelin A (ETA)-Rezeptors richtet, und sich bei 72.7 % respektive 54.5 % der TAO-Patienten nachweisen ließ. AgAAK gegen Epitop 1 oder 2 des Angiotensin-1-Rezeptors wurden bei 3 Patienten, agAAK gegen Loop1/2 des Proteinase-aktivierten Rezeptor (PAR) wurden bei 2 Patienten nachgewiesen. AgAAK gegen den ETA-Rezeptor traten niemals ohne gleichzeitigen Nachweis von agAAK gegen den ?1-adrenergen Rezeptor auf und waren immer gegen Loop1 gerichtet. Unmittelbar nach Beendigung der IA ließen sich bei 81.8 % aller Patienten und bei 77.8 % aller Fälle mit positiven agAAK vor der IA keine agAAK mehr nachgewiesen. Schlussfolgerungen: Wir konnten bei Patienten mit aktiver TAO agAAK gegen GPCR und darüber hinaus ein Antikörper-Cluster nachweisen, das sich bevorzugt gegen Loop1 des ?-1-adrenergen Rezeptors und Loop1 des ETA-Rezeptors richtet. Die agAAK wurden mehrheitlich erfolgreich durch die IA eliminiert. Wir sind der Auffassung, dass gegen GPCR-gerichtete agAAK eine wichtige Rolle in der Pathogenese der TAO spielen und ihre Elimination für die publizierten positiven Effekte der IA verantwortlich sein könnten.Immunhistopathological and serological data favors an immunopathogenesis of thromboangiitis onliterans (TAO, Buerger's disease). Auto antbodies seem to play a major role. Immunoadsorption (IA) proved to be therapeutically effective. We focused on agonistic autoantibodies (agAAB) directed against G-protein coupled receptors (GPCR) and proved the hypothesis, that these agAAB might be present in TAO and that a five day course of IA might be able to eliminate these agAAB effectively.Between December 2012 and May 2014 11 TAO-patients were treated by IA in a five day course. AgAAB-analysis was performed using specific ELISA techniques.AgAAB were detected in 9 out of 11 patients (81.8 %).Multiple agAAB were present in 7 patients (63.6 %). A clustering of agAAB directed against loop1 of the adrenergic ?1-receptor and the endothelin-A-(ETA)receptor was identified, representing 72.7 % resp. 54.5 % of the patients. AgAAB directed against the angiotensin-1 (AT-1) epitope 1 or 2 were detected in 3 patients and agAAB directed against protease-activated receptor (PAR) loop1/2 were seen in 2 patients. AgAAB directed against ETA-receptor loop1 never appeared without agAAB directed against ?1-receptor loop1. Immediately after a five day-course of IA agAAB were absent in 81.8 % of the total study group and in 77.8 % of all cases tested positive for agAAB before IA.AgAAB directed against GPCR were identified in TAO patients with a clustering of agAAB directed against ?-1-adrenergic receptor loop1 and ETA-receptor loop1. AgAA were eliminated by IA in the majority of cases. We suggest that these agAA play an important role in the pathogenesis of TAO and that their elimination might be responsible for the positive therapeutic effects reported in patients treated with IA.","date":"2014-08-22","categories":"Cardiovascular Diseases","split":"test","url":"http://www.ncbi.nlm.nih.gov/pubmed/25147011","annotations":[{"name":"Epitope","weight":0.880674,"wikipedia_article":"http://en.wikipedia.org/wiki/Epitope"},{"name":"Disease","weight":0.804197,"wikipedia_article":"http://en.wikipedia.org/wiki/Disease"},{"name":"Receptor (biochemistry)","weight":0.746318,"wikipedia_article":"http://en.wikipedia.org/wiki/Receptor_(biochemistry)"},{"name":"Pathogenesis","weight":0.735007,"wikipedia_article":"http://en.wikipedia.org/wiki/Pathogenesis"},{"name":"Autoantibody","weight":0.592908,"wikipedia_article":"http://en.wikipedia.org/wiki/Autoantibody"},{"name":"Therapy","weight":0.543289,"wikipedia_article":"http://en.wikipedia.org/wiki/Therapy"},{"name":"G protein-coupled receptor","weight":0.495274,"wikipedia_article":"http://en.wikipedia.org/wiki/G_protein-coupled_receptor"},{"name":"ELISA","weight":0.435248,"wikipedia_article":"http://en.wikipedia.org/wiki/ELISA"},{"name":"Agonist","weight":0.401933,"wikipedia_article":"http://en.wikipedia.org/wiki/Agonist"},{"name":"Serology","weight":0.29127,"wikipedia_article":"http://en.wikipedia.org/wiki/Serology"},{"name":"Thromboangiitis obliterans","weight":0.284824,"wikipedia_article":"http://en.wikipedia.org/wiki/Thromboangiitis_obliterans"},{"name":"Adrenergic receptor","weight":0.135948,"wikipedia_article":"http://en.wikipedia.org/wiki/Adrenergic_receptor"},{"name":"Adrenergic","weight":0.115795,"wikipedia_article":"http://en.wikipedia.org/wiki/Adrenergic"},{"name":"Angiotensin","weight":0.113674,"wikipedia_article":"http://en.wikipedia.org/wiki/Angiotensin"},{"name":"Hypothesis","weight":0.101782,"wikipedia_article":"http://en.wikipedia.org/wiki/Hypothesis"},{"name":"French language","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/French_language"},{"name":"Functional group","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Functional_group"},{"name":"2014","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/2014"},{"name":"Defecation","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Defecation"},{"name":"Chicago Loop","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Chicago_Loop"},{"name":"Sich","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Sich"},{"name":"Ziziphus mauritiana","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Ziziphus_mauritiana"},{"name":"Mesoamerican Long Count calendar","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Mesoamerican_Long_Count_calendar"},{"name":"Study group","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Study_group"},{"name":"Angiotensin II receptor type 1","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Angiotensin_II_receptor_type_1"},{"name":"Film director","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Film_director"},{"name":"Play (theatre)","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Play_(theatre)"},{"name":"Austria","weight":0.0168623,"wikipedia_article":"http://en.wikipedia.org/wiki/Austria"},{"name":"Endothelin","weight":0.0152478,"wikipedia_article":"http://en.wikipedia.org/wiki/Endothelin"},{"name":"Monarch","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Monarch"},{"name":"Rolle","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Rolle"},{"name":"Drug test","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Drug_test"},{"name":"Data","weight":0.0147415,"wikipedia_article":"http://en.wikipedia.org/wiki/Data"},{"name":"Death","weight":0.0143213,"wikipedia_article":"http://en.wikipedia.org/wiki/Death"}]}
